武汉地区43714名献血者血液核酸检测成本效益初步分析  

Cost benefit analysis of 43714 donors blood nucleic acid testing applied to screening in Wuhan,China

作　　者：陆华新[1] 陈国安[1] 姚立[1] 项征国[1] 

机构地区：[1]武汉血液中心,湖北武汉430030

出　　处：《中国输血杂志》2014年第2期164-166,共3页Chinese Journal of Blood Transfusion

基　　金：武汉市公共卫生科研项目(WG12B05)

摘　　要：目的考察武汉地区献血者全血标本核酸检测(NAT)试点的成本效益。方法采用实证分析方法,分析NAT检测43 714(人)份献血者血样HIV、HBV指标的经济收益。结果考虑核酸检测后所避免的HBV感染,武汉地区无偿献血者血液核酸检测的成本效益比为1∶2.5,如果同时将核酸检测后所避免的HIV感染考虑进来,成本效益比为1∶3.6。结论对献血者血液开展NAT检测,不但从社会效益看是必要的,而且成本效益也是合算的。Objective To analyze cost benefit of HBV nucleic acid testing （NAT） and HIV NAT in blood donors in Wuhan. Methods The samples of 43 714blood donors were screened with NAT,and empirical analysis was taken to evalu- ate the cost efficiency of HIV and HBV NAT screening. Results The cost-benefit of HBV NAT screening was 1 ： 2.5 （3.88 million RMB/9.66 miUion RMB）. The cost-benefit was 1 ： 3.6 （3. 88 million RMB/13. 808 million RMB ）, if HIV NAT screening included. Conclusions NAT for screening donor blood is necessary for social benefits, and also worthy in cost.

关 键 词：核酸检测 献血者 成本效益 HIV感染 HBV感染 

分 类 号：R446.1[医药卫生—诊断学]